REGULATION D 506(C) MANDATED LEGEND

Any historical performance data represents past performance. Past performance does not guarantee future results; Current performance may be different than the performance data presented; The Company is not required by law to follow any standard methodology when calculating and representing performance data; The performance of the Company may not be directly comparable to the performance of other private or registered funds or companies; The securities are being offered in reliance on an exemption from the registration requirements, and therefore are not required to comply with certain specific disclosure requirements; The Securities and Exchange Commission has not passed upon the merits of or approved the securities, the terms of the offering, or the accuracy of the materials.

  • Twitter Social Icon
  • LinkedIn Social Icon
  • mailchimp icon

Investment Portfolio

Many Radiology AI companies show enormous potential and are giving Bold Brain Ventures the opportunity to invest early due to the fund’s domain expertise in radiology. Because startups want radiologist input and investment as they develop their solutions, Bold Brain Ventures has a considerable advantage over conventional approaches to investing.

 

The managing partners, Dr. Tomislav Deur and Dr. Robin Prasad, have already personally invested in a select number of startups as proof of concept for deal flow and the ability to execute. This strategy has allowed Bold Brain Ventures to facilitate key connections in the Radiology AI sector and secure an early stake in the companies that look most promising.

 

These investments can be added to the Bold Brain Ventures portfolio at the investment amount initially paid by the managing partners with no additional cost to investors when the fund reaches its first close of $1MM, as long as all Limited Partners agree.

Numerous other companies will be added to the portfolio after the fund reaches first close and as it matures. Bold Brain Ventures will be evaluating these additional opportunities for strategic investment when both the companies and the fund are ready. Many relationships with potential portfolio companies are already in place.

The fund's managing partners have personally invested in the following six companies. Bold Brain Ventures may be able to participate in additional investment rounds in these companies.

 

If you are interested in meeting with the following AI companies in person, most will be exhibiting at the AI Showcase at RSNA 2019 in Chicago from December 1st-6th, 2019. Bold Brain Ventures will be also be exhibiting in the AI Showcase at Booth #10842. We would be happy to meet with you to answer any questions that you might have or discuss opportunities for collaboration.

CureMetrix-LogoFinal_TM.png

Winner - “Best New Radiology Vendor” – Aunt Minnie.com

Delivering CAD That Works®, CureMetrix is committed to the advancement of technology that improves cancer survival rates worldwide. Leveraging artificial intelligence (AI) and deep learning to develop the next generation of medical image analysis, CureMetrix delivers technology that radiologists, healthcare systems and patients can confidently rely on.

 

Key solutions:

  • cmTriage™: The first FDA-cleared software in the U.S. that uses the power of AI to enable radiologists to customize, sort, and prioritize their mammography worklists based on cases that may need immediate attention, allowing for case triage and reduced administration.

  • cmAssist®: A proprietary, investigational SaaS intended to help identify, mark and score regions of interest on screening and diagnostic mammograms.

CureMetrix will be exhibiting at Booth #10115 in the AI Showcase at RSNA 2019 in Chicago.

Inference Analytics has built a platform called Inference Analytics Neural Network (IANN) that uses deep learning to understand the language of healthcare with the goal of improving physician productivity and quality of care. The IANN platform has been trained to solve specific use cases by understanding the language contained within radiology reports. Use cases include protocoling, auto impression suggestion, incidental finding, labeling, and follow-up identification.

Inference Analytics will be co-presenting their results in their impression prediction work with the University of Chicago at RSNA 2019 under the title Abstract ID: 19014879. Title: Prediction of Imaging Report Impression Sections using Sequence to Sequence Long-Short-Term-Memory Neural Network Model with a Customized Healthcare Narrative Cloud Embeddings. (Tuesday 10:30-10:40 AM | SSG06-01 | Room: S406A). You can also visit them at Booth #11145 in the AI Showcase at RSNA.

AI Analysis Logo.jpg

A.I. Analysis Inc. uses machine learning to reduce cost and risk, making radiologists’ lives easier. Through their suite of tools, including the Change Detector for serial image comparison, the Synthetic Enhancement Boost tool for reduced contrast dose, and the T2-FLAIR mismatch detector for biopsy avoidance, they enable radiologists to do things they would not otherwise be able to do. A.I. Analysis makes your life easier, so your practice can be more profitable and you can focus on the high value tasks where you thrive.

 

To learn more about their suite of tools, visit A.I. Anaysis Inc. at Booth #11528 in the AI Showcase

at RSNA 2019.

Mindshare Medical.png

Mindshare Medical is using imaging AI to improve the outcomes and economics of cancer diagnosis. Their first CADx product, RevealAI-Lung, fits within existing clinical workflows for lung nodule diagnosis. The product has been shown to diagnose early while reducing unnecessary follow-up, and has CE Mark and Health Canada licenses. By revealing patterns that are difficult for humans to detect, Mindshare aims to improve quality of patient care and reduce financial liability for healthcare organizations. 

 

Mindshare Medical will be attending RSNA 2019.

Bunkerhill is building an open platform for clinical validation and deployment of AI models for radiology. It will run prospective clinical trials for multiple institutions and integrate algorithms into radiology workflows by introducing a plug & play infrastructure. This streamlined methodology could promote widespread clinical adoption of AI solutions and help solve the last mile problem for AI in medical imaging.

BunkerHill will be attending RSNA 2019.

Koios Medical is a developer of an ultrasound image analysis software platform designed to offer decision support for cancer diagnosis. The company's platform uses artificial intelligence and machine learning to provide a system which is trained on hundreds of thousands of images combined with data from pathology results, enabling healthcare institutions to detect and diagnose cancer with better accuracy along with improving clinical decision making and quality of care.  

Visit Koios Medical at Booth #11329 (AI Showcase) or Booth #3256 (South Hall) at RSNA 2019.